Vance Wealth Inc. Invests $213,000 in Pfizer Inc. (NYSE:PFE)

Vance Wealth Inc. bought a new stake in shares of Pfizer Inc. (NYSE:PFE – Get Rating) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 4,163 shares of the biopharmaceutical company’s stock, valued at approximately $213,000.

Other institutional investors also recently bought and sold shares of the company. Vanguard Group Inc. boosted its stake in Pfizer by 1.1% in the 3rd quarter. Vanguard Group Inc. now owns 493,584,761 shares of the biopharmaceutical company’s stock worth $21,599,270,000 after purchasing an additional 5,139,634 shares in the last quarter. Charles Schwab Investment Management Inc. lifted its stake in shares of Pfizer by 13.2% during the first quarter. Charles Schwab Investment Management Inc. now owns 59,828,849 shares of the biopharmaceutical company’s stock worth $3,097,341,000 after buying an additional 6,972,650 shares during the period. Bank of New York Mellon Corp grew its holdings in shares of Pfizer by 0.6% during the third quarter. Bank of New York Mellon Corp now owns 56,659,179 shares of the biopharmaceutical company’s stock valued at $2,479,407,000 after buying an additional 317,858 shares during the last quarter. Legal & General Group Plc increased its position in shares of Pfizer by 3.2% in the 2nd quarter. Legal & General Group Plc now owns 42,791,672 shares of the biopharmaceutical company’s stock valued at $2,243,574,000 after acquiring an additional 1,336,403 shares during the period. Finally, Dimensional Fund Advisors LP raised its stake in Pfizer by 2.5% in the 3rd quarter. Dimensional Fund Advisors LP now owns 41,242,414 shares of the biopharmaceutical company’s stock worth $1,804,896,000 after acquiring an additional 1,009,399 shares during the last quarter. 67.62% of the stock is currently owned by institutional investors and hedge funds.

Get Pfizer alerts:

Insider Activity

In other news, major shareholder Pfizer Inc acquired 1,811,594 shares of the business’s stock in a transaction that occurred on Friday, March 17th. The shares were purchased at an average price of $2.76 per share, for a total transaction of $4,999,999.44. Following the acquisition, the insider now owns 5,952,263 shares of the company’s stock, valued at $16,428,245.88. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Insiders own 0.05% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have recently weighed in on the company. StockNews.com initiated coverage on Pfizer in a report on Thursday, March 16th. They issued a “buy” rating on the stock. Cantor Fitzgerald reiterated an “overweight” rating and issued a $75.00 price target on shares of Pfizer in a report on Wednesday, February 1st. The Goldman Sachs Group upgraded shares of Pfizer from a “neutral” rating to a “buy” rating and lifted their price objective for the company from $47.00 to $60.00 in a research note on Tuesday, December 13th. JPMorgan Chase & Co. set a $45.00 price objective on shares of Pfizer in a research note on Monday, February 27th. Finally, Berenberg Bank set a $40.00 target price on shares of Pfizer in a research report on Tuesday, February 7th. Eight equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $49.93.

Pfizer Stock Down 0.1 %

Shares of PFE opened at $41.50 on Friday. The stock has a 50 day moving average price of $41.66 and a 200 day moving average price of $45.46. The company has a debt-to-equity ratio of 0.34, a quick ratio of 1.00 and a current ratio of 1.22. The stock has a market capitalization of $234.24 billion, a price-to-earnings ratio of 7.57, a PEG ratio of 1.40 and a beta of 0.64. Pfizer Inc. has a one year low of $39.23 and a one year high of $56.32.

Pfizer (NYSE:PFE – Get Rating) last posted its quarterly earnings results on Tuesday, January 31st. The biopharmaceutical company reported $1.14 EPS for the quarter, beating the consensus estimate of $1.03 by $0.11. Pfizer had a return on equity of 42.03% and a net margin of 31.27%. The firm had revenue of $24.30 billion during the quarter, compared to analysts’ expectations of $24.40 billion. During the same quarter last year, the firm earned $1.08 earnings per share. The business’s revenue for the quarter was up 1.9% on a year-over-year basis. Equities research analysts forecast that Pfizer Inc. will post 3.3 earnings per share for the current fiscal year.

Pfizer Profile

(Get Rating)

Pfizer Inc is a research-based global biopharmaceutical company. It engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases.

Further Reading

• Get a free copy of the StockNews.com research report on Pfizer (PFE)
• MarketBeat Week in Review – 4/3 – 4/7
• Costco Sales Disappoint, Markets Are Missing This Upside Driver
• First Republic Bank Is A Speculative Play, Here’s Why
• The WD-40 Company Bottoms With Reversal In Sight 
• 3 Low-Cost Stock ETFs That Are Crushing It This Year

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.